What Are the Future Directions for Drug Conjugates?
Research in ADCs is rapidly evolving, with several approaches being explored to enhance their efficacy and safety:
- Optimizing Linkers: Developing more stable and selective linkers that release the drug only under specific conditions within the tumor microenvironment. - Bispecific Antibodies: Using antibodies that can bind to two different antigens, potentially increasing the targeting specificity and effectiveness. - Combination Therapies: Combining ADCs with other treatments such as immunotherapy or targeted small molecules to overcome resistance and improve outcomes.
